{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:47:40Z","timestamp":1785854860615,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1097\/01.mbc.0000167658.85143.49","type":"journal-article","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T04:00:44Z","timestamp":1114142444000},"page":"S17-S21","source":"Crossref","is-referenced-by-count":38,"title":["Management of von Willebrand disease with factor VIII\/von Willebrand factor concentrates: results from current studies and surveys"],"prefix":"10.1097","volume":"16","author":[{"given":"Augusto B","family":"Federici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","first-page":"94","article-title":"von Willebrands disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"issue":"suppl 3","key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2516.1998.0040s3007.x","article-title":"Optimizing therapy with factor VIII\/von Willebrand factor concentrates in von Willebrand disease","volume":"4","author":"Federici","year":"1998","journal-title":"Haemophilia"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/beha.2001.0143","article-title":"Management of inherited von Willebrand disease","volume":"14","author":"Mannucci","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1656323","article-title":"Recommended protocol for the study of the ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease (Scientific and Standardization Committee communication)","volume":"68","author":"Mannucci","year":"1992","journal-title":"Thromb Haemost"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","article-title":"Proteolysis of von Willebrand factor in therapeutic plasma concentrates","volume":"83","author":"Mannucci","year":"1994","journal-title":"Blood"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2516.2002.00688.x","article-title":"Clinical efficacy of highly purified, doubly virus-inactivated factor VIII\/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P\u00ae in von Willebrand disease","volume":"4","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1612977","article-title":"Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII\/von Willebrand Factor concentrate, Haemate-P\/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease","volume":"87","author":"Lillicrap","year":"2002","journal-title":"Thromb Haemost"},{"key":"R11-4-20210203","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand factor concentrate, Haemate-P, in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease","volume":"88","author":"Franchini","year":"2003","journal-title":"Haematologica"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1351-8216.2003.00816.x","article-title":"Successful treatment of urgent bleeding in von Willebrand disease with factor VIII\/von Willebrand factor concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.","volume":"9","author":"Gill","year":"2003","journal-title":"Haemophilia"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1351-8216.2003.00809.x","article-title":"Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII\/von Willebrand factor concentrate (Humate-P).","volume":"10","author":"Thompson","year":"2004","journal-title":"Haemophilia"},{"key":"R14-4-20210203","first-page":"1121","article-title":"Dose linearity of von Willebrand factor\/factor VIII concentrate in elective surgery in von Willebrand disease patients.","volume":"102","author":"Mannucci","year":"2003","journal-title":"Blood"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1996.d01-1860.x","article-title":"Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis","volume":"94","author":"Menache","year":"1996","journal-title":"Br J Haematol"},{"key":"R16-4-20210203","first-page":"571","article-title":"Pharmacodynamics of factor VIII coagulant activity in patients with various types of von Willebrand disease after a single von Willebrand factor (VWF) injection","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood.V74.6.1972.1972","article-title":"DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor","volume":"74","author":"Cattaneo","year":"1989","journal-title":"Blood"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.V77.9.1901.1901","article-title":"Hemostatic effect of normal platelet transfusion in severe von Willebrand disease","volume":"77","author":"Castillo","year":"1991","journal-title":"Blood"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2516.2002.00672.x","article-title":"Italian Association of Hemophilia Center (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N Engl J Med"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613227","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","article-title":"Venous thromboembolism in von Willebrand disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"R23-4-20210203","first-page":"212","article-title":"Use of a high-purity factor VIII concentrate (Humate P) in von Willebrand's disease","volume":"56","author":"Berntorp","year":"1989","journal-title":"Vox Sang"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2516.2004.00991.x","article-title":"Clinical diagnosis of von Willebrand disease","volume":"10","author":"Federici","year":"2004","journal-title":"Haemophilia"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006534-200505000-00036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:50:33Z","timestamp":1785851433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200504001-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":25,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mbc.0000167658.85143.49","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}